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Abstract
The transplantation of organs from other species into humans is considered to be a potential solution to the shortage of
human donor organs. Organ transplantation from pig to human, however, results in hyperacute rejection, initiated by the
binding of human natural antidonor antibody and complement. The major target antigen of this natural antibody is the
terminal disaccharide GalK1,3Gal, which is synthesized by GalL1,4GlcNAc K1,3-galactosyltransferase. Here we review our
current knowledge of this key enzyme. A better understanding of structure, enzyme properties, and expression pattern of
K1,3-galactosyltransferase has opened up several novel therapeutic approaches to prevent hyperacute vascular rejection.
Cloning, and expression in vitro of the corresponding cDNA, has allowed to develop strategies to induce immune tolerance,
and deplete or neutralize the natural xenoreactive antibody. Elucidation of the genomic structure has led to the production of
transgenic animals that are lacking K1,3-galactosyltransferase activity. A detailed knowledge of the enzyme properties has
formed the basis of approaches to modify donor organ glycosylation by intracellular competition. Study of the expression
pattern of K1,3-galactosyltransferase has helped to understand the mechanism of hyperacute rejection in discordant
xenotransplantation, and that of complement-mediated, natural immunity against interspecies transmission of
retroviruses. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
During the last 10 years, the number of organ
transplantations has slowly increased. Nevertheless,
in the United States the number of patients on the
waiting list for operation has tripled over the same
period of time (Nature 391 (1998) 325). This situa-
tion is due to the shortage of suitable human organs,
resulting from an increased demand, and an insu⁄-
cient supply. Theoretically, the shortage of donor
organs could be overcome if we would be able to
transplant organs from other animal species into hu-
mans (xenotransplantation). Recently, this alternative
to allotransplantation has become the subject of
widespread medical and commercial interest. Apart
from solving the problem of organ shortage, xeno-
transplantation would o¡er additional advantages:
emergency procedures could be replaced by well-
planned routine operations, and organs would be
obtained from healthy animals. Unfortunately, so
far the history of clinical xenotransplantation has
been disappointing [1], and the survival of xenografts
in human recipients is too short to be clinically
meaningful.
Even when closely related species are used (con-
cordant xenotransplantation) as in primate-to-human
transplantation, a graft usually does not survive for
more than a few days in an untreated host. In addi-
tion, a close evolutionary relationship between donor
and recipient increases the potential risk of the trans-
mission of pathogens. This risk, together with the
limited availability of primates, would favor the use
of other donor species. A multitude of animal species
have been evaluated for their suitability as donor
(ranging from mammals to reptiles and even birds
[2^4]), but many may be too di¡erent physiologically,
or their organs di¡er in structure from those of hu-
mans [5]. Currently, pigs are considered to be the
donor animals of choice. Pigs breed well, are com-
mercially available, and have both physiology and
sizes of organs and vasculature similar to humans.
Also, the use of pigs may generate fewer ethical ob-
jections than that of primates.
Unfortunately, the great phylogenetic distance be-
tween pig and man induces a violent and rapid re-
jection reaction, the so-called ‘hyperacute (vascular)
rejection’ (HAR). Species combinations that result in
HAR are called ‘discordant’. Hyperacute rejection is
antibody- and complement-dependent, and graft fail-
ure may occur within a few minutes to hours after
transplantation. Unlike the rejection occurring upon
concordant transplantation, HAR cannot be pre-
vented by immunosuppressive drugs. Furthermore,
even if HAR can be avoided, a few days later, the
xenograft may still undergo ‘delayed vascular rejec-
tion’, which is also antibody-mediated. In addition,
at later stages (chronic) cellular rejection may occur,
characterized by the in¢ltration of the transplanted
organ by human leukocytes. The involvement of
white blood cells may depend on binding of their
Fc receptors to the Fc portion of antibody bound
to the transplanted organ. In a di¡erent process,
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the recipient’s white blood cells will also extravasate
into the graft tissue via interaction with selectins ex-
pressed on activated endothelium, again leading to
cellular rejection. Interestingly, if HAR can be pre-
vented, for example by temporary removal of the
anti-donor antibody, a process termed ‘accommoda-
tion’ or ‘adaptation’ may occur. When the xenoreac-
tive antibodies gradually reappear the graft is still
recognized as foreign, but is not rejected. In this
case, the transplanted organ may survive for pro-
longed periods of time. The mechanism for accom-
modation is not well known. It may be that in this
situation the xenoantigens have become masked, or
that re-appearance of xenoreactive antibody corre-
lates with a change in repertoire and a decrease in
antibody a⁄nity. Alternatively, it is possible that ac-
commodation can occur because the complement re-
action has weakened.
In this review, we shall focus on the importance of
carbohydrate epitopes (‘glycotopes’) in the hyper-
acute rejection that occurs upon transplantation
from pig-to-human, and on the merits of strategies
to overcome carbohydrate-mediated HAR. The bio-
synthesis of the major carbohydrate xenoantigen is
discussed in detail. The increased knowledge of struc-
ture and properties of the key enzyme involved, K1,3-
galactosyltransferase, has allowed the design of var-
ious novel therapeutic strategies.
2. Natural human anti-carbohydrate antibodies and
xenograft rejection
Rejection of a discordant xenograft by an unmodi-
¢ed primate recipient will usually occur within a few
hours after transplantation. In most experimental
systems, the factors that initiate and sustain a
HAR involve binding of a preformed ‘natural’ anti-
body to the vascular endothelium of the xenograft.
These natural antibodies, found in all higher pri-
mates without any known sensitizing event, are
absent at birth, but develop within a few weeks
or months thereafter. They may arise as a result of
colonization of the gastrointestinal tract by micro-
organisms, and often display a speci¢city for car-
bohydrates. In HAR, antibody binding leads to
complement activation via the classical pathway. It
seems likely that a rapid endothelial cell activation
occurs, resulting in hemorrhage and edema of inter-
stitial tissues, and thrombosis of the smaller vessels
of the graft [6,7]. Immunopathological analysis
showed that the same sequence of events occurs in
an ex vivo pig-to-human lung transplantation model
[8], in which pig lung was perfused with untreated
human blood. Pulmonary dysfunction and failure
occurred within 60^150 min of reperfusion. The
HAR as observed in this model is similar to that
observed in patients receiving organ transplants
from an ABO-incompatible donor [9,10].
In the case of allotransplantation involving an
ABO-incompatible donor, a natural antibody in the
recipient’s blood stream binds to the vascular endo-
thelium of the donor organ. This antibody reacts
with the A or B histo blood group carbohydrate
antigens (see Fig. 1 for structures) present on the
surface of the endothelial cells. Certain aspects of
the rejection observed in discordant xenotransplanta-
tion are similar to this reaction, and therefore it was
hypothesized that most likely, natural antibodies are
also responsible for HAR of discordant xenografts.
The involvement of such antibodies is consistent with
the rapid kinetics of HAR, which precludes an
evoked immune response. In addition, HAR is char-
acterized by the deposition of antidonor antibodies
onto the graft, and it has been observed that the
depletion of natural antibodies prior to transplanta-
tion prolongs the survival of a vascularized graft. It
was proposed that in HAR occurring upon pig-to-
human transplantation, a human natural anticarbo-
hydrate antibody might be involved, which recog-
nizes porcine carbohydrate antigens. The latter xen-
oantigens are di¡erent from the ABO determinants,
as the reaction is independent of the recipient’s blood
group status. Cooper and co-workers [11,12] per-
fused pig heart and kidney with human plasma,
and then eluted bound human antibodies from the
surface of the organs. In this way, both IgG, IgM
and IgA were obtained, which were tested against
various synthetic carbohydrates. Surprisingly, it was
found that the major proportion of the antibody
recognizes a single determinant, a disaccharide of
the structure GalK1,3Gal (often termed the ‘K-gal’
glycotope, Fig. 1) [11^13]. This observation was con-
¢rmed by Parker et al. [14].
The anti-pig natural antibody was thus found to
have the same speci¢city as a human anti-GalK1,3-
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Gal antibody that was ¢rst described by Galili et al.
[15]. This antibody constitutes the most abundant
natural antibody in almost all human sera, and in
certain individuals it may account for as much as
1% of the total circulating Ig [16]. Initially, it was
assumed that this antibody consisted mostly of
IgG. However, more recent analyses have estab-
lished that also IgM and IgA species with the same
anticarbohydrate speci¢city occur in humans
[11,12,17,18]. It has been suggested that during
HAR of a xenograft it is the binding of IgM which
initiates the complement reaction at the surface of
the donor organ endothelium, whereas anti-GalK1,3-
Gal IgG, by competing with IgM, could play a pro-
tective role instead [19]. In addition, Galili [20]
showed that the anti-GalK1,3Gal antibody could me-
diate the antibody-dependent cellular cytotoxicity of
human monocytes against porcine cells in tissue cul-
ture.
Earlier, it has been shown that the anti-GalK1,3-
Gal antibody displays a species-speci¢c distribution
[21]. The antibody can be detected in humans, apes
and Old World monkeys, but is absent from the
circulation of all other mammals, including the
New World monkeys. It has been suggested that
continuous production of this natural antibody is
due to the immune stimulation by gastrointestinal
bacteria that express a variety of carbohydrate anti-
gens, including the K-gal glycotope [22]. The presence
of the antibody in the human circulation is the main
cause of HAR in pig-to-man xenotransplantation.
3. Occurrence of the GalK1,3Gal antigen
The disaccharide GalK1,3Gal is found at the non-
reducing terminus of protein- and lipid-bound gly-
cans, and the K-linked galactose is a non-charged
alternative to sialic acid as a chain terminator (Fig.
2). The K-gal glycotope is di¡erent from the blood
group B determinant. Although both structures share
the GalK1,3Gal motif, they di¡er in that a fucosyl
residue is an essential part of the B determinant,
whereas this fucosyl residue is absent in the K-gal
glycotope (Fig. 1). The GalK1,3Gal structure is ela-
borated by a speci¢c K1,3-galactosyltransferase that
is distinct from the blood group B galactosyltransfer-
ase (see Section 4).
GalK1,3Gal structures have been detected in a va-
riety of mammalian species. Only cells and tissues
derived from catarrhines (humans, apes and Old
World monkeys) do not express the K-gal glycotope,
and in this respect these species di¡er from all other
mammals [22]. Interestingly, New World monkeys,
which separated from the catarrhines only V40 mil-
lion years ago, continue to express the epitope. These
data are consistent with earlier results obtained by
Spiro and Bhoyroo [23], who showed that the glyco-
protein thyroglobulin displays a species-speci¢c K1,3-
galactosylation of its N-glycans. It seems, therefore,
that the expression of K-gal glycotopes is comple-
mentary to the distribution of the natural anti-
GalK1,3Gal antibody [21].
Most non-mammalian species that have been ex-
amined to date appear not to express GalK1,3Gal
glycotopes, with the possible exception of the cobra
Naja naja kaouthia [4]. Carbohydrate analysis of co-
bra venom glycoproteins showed that O-linked poly-
lactosaminoglycans of mucin-like proteins are termi-
nated by K1,3-linked galactose or K1,3-galactosylated
Lewisx structures [24,25]. The egg glycoproteins (hy-
osophorins) of several teleost ¢sh species were also
found to contain glycans terminated with the struc-
ture GalK1,3Gal [26].
The K-gal glycotope is found both on mammalian
tissues and cells in tissue culture. In the mouse, Grif-
fonia simplicifolia I-B4 (GSI-B4) lectin staining has
detected GalK1,3Gal structures in a variety of organs
and cell types, with the exception of liver [27]. Ex-
pression levels of the GalK1,3Gal glycotope in mouse
liver seem to be strain-dependent, though, as DBA/2
Fig. 1. The GalK1,3Gal glycotope and the blood group B anti-
gen. (a) The major porcine xenoantigen, a disaccharide with the
structure GalK1,3Gal. (b) The blood group B antigen, with the
structure GalK1,3[FucK1,2]Gal. (c) The blood group A antigen,
GalNAcK1,3[FucK1,2]Gal. b, galactose; E, N-acetylgalactos-
amine; v, fucose.
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mice unlike Balb/c show a weak positive reaction
[28]. In contrast, using GSI-B4 lectin, both Cooper
et al., and Sandrin and McKenzie, found that the
parenchyma of porcine liver contains K-linked galac-
tose residues [28,29]. However, more recently Oriol et
al. showed that, although pig hepatocytes react with
GSI-B4, the reaction cannot be abolished by K-gal-
actosidase treatment of the cells. Most likely, the
observed lectin binding is an artifact due to the pres-
ence of the asialoglycoprotein receptor at the cell
surface [4]. In another lectin- and immunostaining
analysis of porcine tissues, Oriol et al. [30] detected
various carbohydrate antigens on endothelial cells.
Vascular endothelium showed a strong reactivity
with reagents speci¢c for K-galactosylated structures,
although in addition, sialylated structures are
present. The K-gal glycotope was also present on
erythrocytes, leukocytes and platelets. In general, ¢-
ner details of the GalK1,3Gal expression pattern may
di¡er from species to species (e.g. between pig and
mouse), but consistently, high-level expression is
found on the endothelial cells of all capillaries, arte-
rioles and arteries, the ¢rst point of contact between
antibodies and donor organ.
Cairns et al. [31] and Vaughan et al. [32] have
detected on pig vascular endothelium both GalK1,3-
Gal containing glycoproteins and glycosphingolipids.
Detailed structural analyses of the xeno-epitope have
been carried out by Samuelsson and colleagues [33^
35], who showed that the major K1,3-galactosyl-
ated glycosphingolipid on porcine endothelium is ce-
ramide-pentahexoside (GalK1,3GalL1,4GlcNAcL1,3-
GalL1,4Glc-ceramide, see Fig. 2). The protein-linked
glycans contain the GalK1,3GalL1,4GlcNAc trisac-
charide at their non-reducing terminus (Fig. 2). In-
terestingly, the major endothelial cell surface glyco-
proteins carrying the GalK1,3Gal glycotope were
identi¢ed as Von Willebrand factor, and various in-
tegrins [36]. More sensitive procedures, however, de-
tected multiple additional K1,3-galactosylated cell
surface proteins, expressed at lower levels [28,37].
4. Synthesis of the GalK1,3Gal xenoantigen by
K1,3-galactosyltransferase
4.1. The enzyme K1,3-galactosyltransferase
Xenoantigens that contain the GalK1,3Gal struc-
ture are produced by UDP-Gal:GalL1,4GlcNAc
K1,3-galactosyltransferase (K3GalT, EC 2.4.1.87).




in which R may be glycoprotein or glycolipid [38].
N-Acetyllactosamine (GalL1,4GlcNAc) is the pre-
ferred substrate for the enzyme; lactose (GalL1,4Glc)
is also recognized as an acceptor, but its Km is 6^7-
fold higher. Both protein- and lipid-linked lactosami-
noglycans are excellent substrates for K3GalT. Im-
portantly, the enzyme cannot transfer to fucosylated
substrates such as the blood group H structure
(FucK1,2GalL1,3/4GlcNAc), and therefore is unable
to produce the blood group B determinant. In this
respect, it is di¡erent from the blood group B K1,3-
galactosyltransferase. Also, the Lewisx structure
(GalL1,4[FucK1,3]GlcNAc) is not an acceptor sub-
strate for K3GalT. Fig. 3 shows the reaction products
of the blood group B transferase and K3GalT.
A good glycolipid acceptor substrate for K3GalT is
Fig. 2. Terminal structures of glycoprotein and glycolipid gly-
cans. (a) A diantennary N-glycan. In mammals, complex-type
and polylactosamine chains are often terminated by sialic acid
or K1,3-linked galactose. (b) Ceramide-pentahexoside, GalK1,3-
GalL1,4GlcNAcL1,3GalL1,4Glc-ceramide. Terminal structures
shown are the K-gal glycotope (GalK1,3Gal) (boxed) and the
NeuAcK2,6Gal structure (boxed with dashed line). Alterna-
tively, N- and O-glycans can be terminated by blood group de-
terminants (GalK1,3[FucK1,2]GalL1-R, GalNAcK1,3[FucK1,2]-
GalL1-R, or FucK1,2GalL1-R), polysialic acid, or sulfate
groups. The same terminal structures can be found on both gly-
coprotein N- and O-glycans and glycolipids. F, N-acetylglucos-
amine; a, mannose; b, galactose; 8, glucose; W, sialic acid;
O, fucose.
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lacto-N-neotetraosylceramide (GalL1,4GlcNAcL1,3-
GalL1,4Glc-ceramide), but the enzyme cannot use
lactosylceramide (GalL1,4Glc-ceramide). It is not
yet known whether the protein portion of a glyco-
protein acceptor can interact with K3GalT, and in
this way a¡ect galactosyl transfer to the glycans it
carries. Such acceptor protein preference might ex-
plain the observation that only a limited number of
major, K1,3-galactosylated glycoproteins is detected
on porcine endothelial cells (see above).
4.2. The K3GalT gene family
Genes and cDNAs encoding K3GalT have been
cloned from several di¡erent species [39^44]. The bo-
vine K3GalT cDNA was the ¢rst to be isolated [39],
and the properties of the corresponding enzyme have
formed the basis for subsequent studies. The enzyme
was puri¢ed from thymus by use of a⁄nity chroma-
tography on UDP-Sepharose [38], and the K3GalT
cDNA was then isolated from a bovine cDNA li-
brary by immunoscreening using an anti-K3GalT
antibody and K3GalT-speci¢c oligonucleotide probes
[39]. A 1836-bp cDNA was cloned that encoded a
368-amino acid protein. The coding sequence pre-
dicted a type II transmembrane protein, consisting
of a 6-amino acid amino-terminal cytoplasmic tail,
a transmembrane domain (signal anchor sequence)
of 19 residues, and a large, carboxy-terminal cata-
lytic domain of approximately 280 amino acids (see
Fig. 4). The catalytic domain is linked to the trans-
membrane domain via a V60-amino acid hydro-
philic linker apparently devoid of secondary struc-
ture, termed the ‘stem region’. More recent studies
[42] have con¢rmed that the K3GalT catalytic do-
main is likely to be contained in the carboxy-terminal
V286 amino acid residues.
Other mammalian K1,3-galactosyltransferase or-
thologs: cDNAs encoding mouse K3GalT were ob-
tained from F9 cells by expression cloning [40], and
by homology screening of a cDNA library using the
bovine cDNA as a probe [41]. The two murine
cDNAs predict polypeptides that di¡er in the length
of the stem, as a result of alternative splicing. Com-
parison of the full-length murine protein, derived
from the genomic sequence, with bovine K3GalT re-
vealed a 73% identity at the amino acid level. A large
number of di¡erences are present in the stem region,
whereas a high degree of similarity (79% identical
amino acids in 286 residues) is found in the car-
boxy-terminal portion of the enzyme which contains
the putative catalytic domain.
Homologous sequences from marmoset (a New
World monkey) [42] and pig [43,44] were cloned by
library screening using the murine K3GalT cDNA as
a probe. Again, there is a high degree of similarity in
the carboxy-terminal 250 amino acid residues when
this region is compared with K3GalTs from other
mammalian species. Partial K3GalT sequences were
obtained from various species of primates by use of
PCR [45]. The human genome was found to contain
two homologs of the K3GalT gene [46,47]. However,
Fig. 4. Schematic of the protein domain structure of K3GalT.
The cytoplasmic tail, the transmembrane domain (TMD), the
stem region and the catalytic domain are indicated. A single N-
glycan is attached to the catalytic domain at Asn-293 (indicated
as a, not drawn to scale). Proteolysis in the stem region of the
enzyme (arrows) would result in the secretion of a truncated,
soluble, enzymatically active protein.
Fig. 3. Reactions catalyzed by K3GalT and the blood group B
K1,3-galactosyltransferase. Fucosylated acceptors such as
FucK1,2Gal or GalL1,4[FucK1,3]GlcNAc cannot be K1,3-galac-
tosylated by K3GalT. In contrast, a non-fucosylated acceptor,
such as GalL1,4GlcNAc, is not a substrate for the blood group
B transferase. The X indicates a reaction that does not occur.
For symbols, see Fig. 2.
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both genes are pseudogenes, and apparently neither
gives rise to a transcript (see below).
Extensive sequence similarities exist between the
mammalian K1,3-galactosyltransferase orthologs
[39^45], the ABO blood group transferases [48,49],
Forssman K1,3-GalNAc-transferase [50], and related
pseudogenes [46,51]. Together these genes form the
K3GalT gene family (cf. Breton et al. [52]). The ex-
tent of amino acid sequence conservation between
the mammalian K3GalT orthologs is in the order
of 73^88%. The similarity with the human blood
group transferases is of special interest in view of
the shared chromosomal localization of these genes
with one of the human K3GalT homologs. In addi-
tion, their genomic organization is similar: both the
human ABO genes and the (murine) K3GalT gene
have their protein coding sequence distributed over
multiple exons, while the major portion of the coding
sequence is present on a single large exon [41,53].
The latter exon is likely to encode almost all
(V230 amino acids) of the catalytic domain (Fig.
4). These observations point to a close evolutionary
relationship between K3GalT and the blood group
transferases.
4.3. Species-speci¢c expression of K3GalT
The expression of K3GalT is usually inferred from
direct enzyme activity assays, or from the detection
of K3GalT transcripts. The expression of K3GalT
seems to be restricted mainly to mammals, although
it is possible that related enzymes are present in cer-
tain species of ¢sh and snakes. Earlier, we have
shown that although the human genome contains
gene sequences homologous to mammalian K3GalT
[39], no transcripts are detected in human cell lines in
tissue culture. Similarly, no K3GalT transcripts are
detected in a number of cell lines from apes and Old
World monkeys. Most likely, mutation(s) have oc-
curred in the upstream regulatory sequence of the
K3GalT gene in catarrhines, resulting in a suppres-
sion of transcription.
In contrast, enzyme expression can be detected in
most mouse and rat tissues and organs, as deter-
mined by direct enzyme activity assays, and RT-
PCR. However, mouse liver seems to be devoid of
K3GalT both on enzyme assay and transcript detec-
tion (Joziasse, D.H., unpublished observation, and
[54]). In addition, murine male germ cells do not
contain K3GalT transcripts [41,55]. In mice in which
the K3GalT gene has been inactivated via homolo-
gous recombination, no enzyme activity is detectable,
and no GalK1,3Gal structures can be detected on the
various tissues [56,57]. This is consistent with our
earlier observation that murine K3GalT is encoded
on a single gene [58]. In general, it appears that the
expression of K3GalT activity parallels the species-
speci¢c expression of K-gal glycotopes.
An K1,3-linked galactose is also present in trihex-
osylceramide, which has the structure GalK1,3-
GalL1,4Glc-ceramide. However, as K3GalT cannot
use lactosylceramide (GalL1,4Glc-ceramide) as a sub-
strate (see 4.1), trihexosylceramide must be the prod-
uct of a di¡erent K1,3-galactosyltransferase, as de-
tected in rat spleen and bone marrow [59]. Also, a
globoside containing the structure GalK1,3GalK1,4-
R, and more extended globosides with internal re-
peats of K1,3-linked Gal residues, are present in rat
small intestine and in rat pheochromocytoma cells
(PC12h) [60]. The K1,3-galactosyltransferase involved
in the synthesis of such glycosphingolipids has been
characterized in detail [61]. It may be related to
K3GalT, but as yet no sequence information is avail-
able.
The lack of K3GalT expression in humans, apes
and Old World monkeys does not seem to have a
deleterious e¡ect. On the other hand, transgenic
mice in which the functional K3GalT gene has been
inactivated by homologous recombination remain
healthy and appear normal, but do develop eye cat-
aracts [57]. It is possible that the occurrence of this
problem is limited to the mouse. If so, one may won-
der why most mammalian species have maintained
the functional gene. Various glycosylation polymor-
phisms are known (e.g. in the human ABO blood
groups, and the expression of certain K1,2-fucosyl-
transferases), but do not seem to be connected with
an evolutionary advantage. Curiously so far no poly-
morphism has been detected in the expression of
K3GalT in pigs [4,10,62], but it is possible that there
are animals in which one of the two copies of the
K3GalT gene is inactive. Such heterozygosity would
go unnoticed, as expression from a single, active gene
copy is anticipated to generate su⁄cient K3GalT ac-
tivity to confer the K-gal phenotype on pig glyco-
proteins. Therefore, there is no reason to expect se-
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lection against heterozygotes per se. Theoretically,
breeding of these heterozygotes, once identi¢ed,
might generate homozygous null mutants. However,
it remains to be seen if these null mutants would
be viable, and develop normally. Failure of these
animals to reach adulthood would, under natural
conditions, a¡ect the breeding e⁄ciency of heter-
ozygotes, and ultimately select for K3GalT
homozygosity.
Conversely, it has been suggested that host^patho-
gen interactions have provided the selective pressure
to inactivate the K3GalT gene in the catarrhines.
Two mechanisms can be considered. Non-reducing
terminal saccharide structures are functionally im-
portant in the binding of pathogenic microorganisms
to mammalian cells. A change in the glycan struc-
tures that are expressed at the mammalian cell sur-
face may abolish speci¢c pathogen binding, and thus
protect the host. Also, an individual with altered
glycosylation might be able to produce a di¡erent
spectrum of natural anticarbohydrate antibodies,
which may provide protection against speci¢c patho-
genic bacteria and viruses (cf. Section 7, and [63,
64]). An example of such situation may be found
in the ABO polymorphism [65]. Neither of the two
mechanisms, however, seems su⁄cient to explain
how heterozygosity at the K3GalT locus might
have conferred an evolutionary advantage, as the
inactivation of both gene copies is required for a
change in cellular glycosylation. It is conceivable,
though, that K-gal3 o¡spring may show a higher
breeding e⁄ciency, which would select for K3GalT3
homozygosity.
5. Molecular evolution of the K3GalT gene family:
inactivation of the K3GalT gene
In the human genome, K3GalT is represented by
two pseudogenes, HGT-2 and HGT-10 [46]. One of
these genes, HGT-2, has the characteristics of a pro-
cessed pseudogene, the other (partial) gene, HGT-10,
is likely to be the missing 5P portion of a human
K3GalT sequence that was isolated by Larsen et al.
[47]. The latter gene, like HGT-2, contains multiple
insertions, deletions, and point mutations that result
in premature stop of translation. It contains several
introns, and is likely to be the remnant of the once
functional gene in humans. In view of the shared
localization of human K3GalT homolog HGT-10
and the ABO locus on chromosome 9q34 [66], the
observed sequence similarity between the ABO blood
group transferases and K3GalT, and their similar ge-
nomic organization, it is hypothesized that these
genes originate from a single ancestral gene (Fig.
5). After tandem duplication of the ancestral gene
V400 million years ago [65], one gene copy might
have evolved into the ABO genes, and the other one
into the human K3GalT gene sequence on chromo-
some 9 represented by HGT-10. At some point in
time, after the divergence of New World monkeys
from the catarrhines, the human K3GalT gene may
have given rise to an mRNA that, after reverse tran-
scription, was inserted into chromosome 12.
It has been shown by gene cloning and PCR anal-
ysis that during the course of evolution, the K3GalT
gene has been inactivated in the catarrhines (Old
World monkeys, apes and man), although it contin-
ues to be functionally expressed in most other species
of mammals including the New World monkeys
[22,45^47]. Homologs of the K3GalT gene are
present in the genome of apes and Old World mon-
keys, but they are pseudogenes like their human
counterparts [46]. Their coding sequence contains
multiple frame shift mutations; therefore, these genes
are not anticipated to encode an enzymatically active
Fig. 5. A model of the evolution of the K3GalT gene family
and the inactivation of the K3GalT gene in catarrhines. Dupli-
cation of the ancestral gene may have occurred V400 million
years ago. Subsequent divergence of the two gene copies has
given rise to the ABO blood group genes and K3GalT.
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protein. Focusing on these frameshift mutations,
Galili concluded that gene inactivation in apes was
a relatively recent event, and that separate gene in-
activating events have occurred in the Old World
monkeys on the one hand, and in apes and humans
on the other, after the two groups diverged from
each other [45].
However, we prefer a simpler, previously suggested
model [67] in which the K3GalT gene was inactivated
in the lineage of the catarrhines by a single event
(compare Fig. 5). This event, the introduction of a
stop codon at amino acid position Tyr-263 (bovine
sequence) occurred after the divergence between ca-
tarrhines and the New World monkeys, but prior to
further divergence of the catarrhines. DNA sequence
analysis has shown that the mutation to TAG inter-
rupts the coding sequence in all Old World monkey
and ape sequences analyzed thus far [45,67]. The
same mutation is present in the partial human
K3GalT pseudogene sequence isolated by Larsen et
al. [47]. This sequence is likely to be part of human
pseudogene HGT-10, located on chromosome 9 [46],
presumably the original, once functional K3GalT
gene in hominids. The nonsense mutation leads to
a premature termination of translation, resulting in
gene inactivation. The mutation is absent in all spe-
cies that express an active K3GalT homolog (New
World monkeys, cow, pig and mouse), where the
codon reads TAC or TAT (Tyr). Importantly, the
same mutation is present in the human processed
pseudogene HGT-2, which may suggest that tran-
scription of the gene continued for a certain period
of time even though translation of the mRNA would
have yielded a truncated, enzymatically inactive pro-
tein. Such transcription of a glycosyltransferase pseu-
dogene is similar to what is observed today for the
blood group type O. We have estimated the age of
the processed pseudogene HGT-2 to be V25 million
years [46]. As the catarrhines and New World mon-
keys diverged V40 million years ago, this would
mean that K3GalT inactivation has occurred between
25 and 40 million years ago. At the time when HGT-
2 originated, the source gene continued to be tran-
scribed, but must already have contained the stop
codon at amino acid position 263. An additional
mutation in the regulatory sequences of the source
gene must have occurred somewhat later in evolu-
tion, resulting in the current lack of transcription
in the catarrhines.
From the sequence di¡erences between the human
pseudogene HGT-10 and the New World monkey
sequences (4.6^7.0%), it can be calculated that gene
inactivation may have taken place between 22 and 32
million years ago [45]. Most of this period overlaps
with the 15-million year window as de¢ned above.
This would be consistent with a scenario in which
gene inactivation through the insertion of a stop co-
don occurred prior to the divergence of apes from
Old World monkeys (20^28 million years ago), and
explain the presence of this stop codon in all K3GalT
pseudogenes.
6. Strategies to prevent HAR in discordant
xenotransplantation
Various approaches have been considered to pre-
vent hyperacute rejection upon organ transplantation
from pig to humans. We can distinguish a suppres-
sion of the immune reaction, the induction of im-
mune tolerance in the recipient, or a modi¢cation
of the tissues of the donor. The HAR reaction may
be prevented by blocking, or depletion of the natural
anti-GalK1,3Gal antibody. With respect to a modi¢-
cation of the donor tissue, an alteration of the gly-
cosylation phenotype of the tissue is being considered
in order to suppress the expression of the GalK1,3-
Gal glycotope. Another approach is based on the
expression of human complement-regulatory proteins
on donor endothelial cells.
6.1. Antibody depletion
In case of allotransplantation across the ABO
blood group barrier, depletion of the anti-A (or
anti-B) antibody is required prior to transplantation.
It has been shown clinically that removal of the anti-
blood group natural antibody does enable ABO in-
compatible transplantation [29]. It is possible to re-
move all Ig’s by plasmapheresis, but this may leave
the recipient susceptible to infection and thrombo-
genic disorders. This is why a speci¢c removal of
the anti-donor antibodies is preferred. Antibody
can be depleted by extracorporeal immunoadsorp-
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tion on a⁄nity columns that carry the blood group
antigen of interest. The temporary reduction in anti-
body levels prevents HAR, and may result in accom-
modation.
A similar approach has been proposed in the case
of pig-to-human xenotransplantation. Here, immu-
noadsorption can be accomplished on a⁄nity col-
umns carrying the major pig xenoantigen, GalK1,3-
Gal-R. It is interesting to note that the
GalK1,3GalL1,4Glc trisaccharide glycotope (type 6)
seems to have a higher a⁄nity than the GalK1,3-
GalL1,4GlcNAc (type 2) structure [68], even though
it is well known that K3GalT prefers the type 2 struc-
ture N-acetyllactosamine as an acceptor over lactose
(see above). It is not clear, though, to what extent the
presence of the hydrophobic spacer that links the
oligosaccharide to the column may a¡ect the binding
properties of the oligosaccharides. Furthermore, it
has been shown that a recombinant mucin such as
PSGL-1, carrying multiple copies of the GalK1,3Gal
glycotope, is also an e⁄cient immunoadsorbant [69].
The glycans attached to this glycoprotein may struc-
turally be more similar to the natural xenoantigen
than the oligosaccharides linked to a⁄nity matrices,
and may o¡er a more varied range of structures. As
the anti-K-gal antibody is heterogenous in its prefer-
ence for di-, tri-, or pentasaccharide structures [70],
the mucin may thus allow a more complete antibody
adsorption. Alternatively, xenoreactive antibodies
can be removed via a perfusion of the recipient’s
blood through pig organs [71]. The e⁄ciency of im-
munoadsorption in reducing serum cytotoxicity
against porcine endothelial cells in tissue culture
was shown in various in vitro studies [72^74]. Lastly,
the use of anti-idiotype antibodies has also been pro-
posed as a means to reduce the binding of xenoreac-
tive antibodies [75]. Apparently, the xeno-reactive
natural antibodies have a limited idiotope diversity,
which is why combination of only a few anti-idiotype
antibodies is su⁄cient for blocking.
Of course, it remains to be investigated if tempo-
rary depletion of the antibody will be su⁄cient to
ensure long-term transplant survival. Upon termina-
tion of the treatment, there is a rapid reversal (within
4 days) of natural antibody titers. However, it is
hoped that if hyperacute rejection can be prevented,
accommodation may occur as in ABO incompatible
transplantation. A continued pharmacologic immu-
nosuppressive therapy will be necessary, though, to
prevent the development of cellular rejection, and
perhaps to reduce the production of new antibody,
while accommodation is taking place.
6.2. ‘Neutralizing’ oligosaccharides
The alternative to immunoadsorption is the intra-
venous infusion into the recipient of oligosaccharides
that mimic the xenoantigen, a treatment which has to
be applied both prior to and following xenotrans-
plantation in order to be e¡ective. This method, in
which a blood group trisaccharide was infused into
the recipient, has been successful in allowing ABO-
incompatible cardiac allografting in the baboon
[76,77]. In a similar way, intravenous infusion of
GalK1,3Gal oligosaccharides was shown to reduce
baboon serum cytotoxicity to transplanted pig hearts
[74,78], and to delay HAR [79]. The same protective
e¡ect was observed when pig kidney (PK-15) and
vascular endothelial cells in tissue culture were ex-
posed to human or baboon serum to which GalK1,3-
Gal oligosaccharides had been added [74,80]. Cyto-
toxicity was not abolished by a variety of other
carbohydrates, which underlines that the exact struc-
ture of the GalK1,3Gal oligosaccharides used for
blocking or immunoadsorption should closely resem-
ble the porcine xenoantigen. It is likely that porcine
tissues contain the disaccharide at the non-reducing
terminus of both glycoprotein and glycolipid glycans
(see above), as part of the structure GalK1,3-
GalL1,4Glc(NAc)L1-R. It was found that both the
Table 1
‘Neutralizing’ oligosaccharides
Inhibitor oligosaccharide Concentration of oligosaccharide
(WM)
Human serum Baboon serum
GalL1-R s 10 000 s 10 000




The concentration of oligosaccharide corresponds to the con-
centration that is required for a 50% inhibition of cytotoxicity
of unmodi¢ed human or baboon serum against pig PK-15 cells
[81]. R represents a 1,3- or 1,4-linkage to an underlying sugar
residue. RP is the hydrophobic linker ^O(CH2)3-NHCOCF3.
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length of the inhibitor, and the proper structure of
both the reducing and the non-reducing end of the
oligosaccharide are important for achieving su⁄cient
inhibitory activity [72,81]. Essential is the correct
linkage type (i.e. K1,3) between terminal and subter-
minal sugar residue (see Table 1). Compounds con-
taining GalK1,2Gal or GalK1,6Gal structures are less
e⁄cient, and modi¢cation of the linkage type of the
non-reducing terminal sugar from K to L completely
abolishes the inhibition of cytotoxicity. Also, the tri-
saccharides GalK1,3GalL1,4GlcNAc and GalK1,3-
GalL1,4Glc are at least 10-fold more e⁄cient inhib-
itors than the disaccharide GalK1,3Gal. These
observations point to a rather narrow speci¢city of
the natural human antibody.
The various compounds used in clinical studies are
needed in rather high amounts (grams to kilograms).
They can be produced by organic or chemo-enzy-
matic synthesis, and glycosyltransferase-catalyzed
synthesis in particular is highly e¡ective. This meth-
od takes advantage of the availability of recombinant
K1,3-galactosyltransferase (produced in insect cells
[82], or bacteria [83]) and a variety of other recombi-
nant glycosyltransferases [84], and of the absolute
regio- and stereo-selectivity of these enzymes. For
large-scale synthesis, it is essential to be able to re-
generate expensive nucleotide sugars in situ [85,86],
preferentially in a one-pot synthetic reaction. Oligo-
saccharide inhibitors may also be produced in alter-
native systems. Recently, it has been proposed to use
recombinant bacteria, expressing the appropriate gly-
cosyltransferases, as micro-fermenters to produce the
desired oligosaccharides (R. Geremia, personal com-
munication). Various glycosylhydrolases have also
been applied in oligosaccharide synthesis. These en-
zymes show a good stereo-selectivity, and do not
require nucleotide sugars, but are of limited regiose-
lectivity [84,86].
Alternative approaches have been developed in
which high-molecular weight natural glycoproteins
are used as blockers (e.g. pig stomach mucin),
although there is a risk that these compounds may
induce an immune reaction, and perhaps may lead to
the formation of harmful antigen^antibody com-
plexes. Another disadvantage is that the active moi-
eties are not always well de¢ned. In an improved
procedure the O-glycans of these mucins have been
prepared by L-elimination, and were shown to be
e⁄cient inhibitors of primate serum cytotoxicity
against pig PK-15 cells in vitro [87].
Importantly, there is a large di¡erence in a⁄nity
between IgG and IgM, both components of the nat-
ural xenoreactive antibody. It has been found that
whereas monovalent compounds in micromolar con-
centration can block IgG, more e⁄cient blockers are
needed to inhibit IgM binding. For this purpose,
speci¢c multivalent compounds have been developed
by Bovin and co-workers [88], made of spacered oli-
gosaccharides attached in a multivalent fashion onto
a polyacrylamide backbone (activated polymer, poly-
(4-nitrophenylacrylate)). These compounds were
found to be highly e⁄cient blockers of IgM binding,
as compared to monovalent compounds. Also, ad-
sorption columns carrying the multivalent polyacryl-
amide derivatives were constructed, and were shown
to be e⁄cient immunoadsorbants [72].
A quite di¡erent approach towards the induction
of immune tolerance was reported recently [89]. By
recombinant retroviral transduction of the bone mar-
row, an K3GalT genotype was induced in K3GalT3
knock-out mice, which as a result of the gene inacti-
vation produce a natural anti-K-gal antibody, like
primates. The expression of the K-gal glycotope in
their bone marrow e¡ectively abolished the produc-
tion of the natural antibody [89]. It is conceivable
that a similar treatment of a human recipient prior
to transplantation of a pig organ might induce im-
mune tolerance towards the carbohydrate xenoanti-
gen on porcine tissues.
6.3. Modi¢cation of the donor organ
Even though in many respects HAR in ABO in-
compatible transplantation is similar to that ob-
served in pig-to-human organ transplantation, it
may be less severe as the complement reaction is
modulated by complement inhibitory proteins. How-
ever, in case of xenotransplantation, the modulation
is less e⁄cient as complement-regulatory proteins
tend to be species-speci¢c. This has led to the idea
of producing transgenic pigs that express proteins
such as human DAF, an inhibitor of the complement
reaction, on their endothelial cells [90,91]. Indeed,
this strategy has prevented the occurrence of HAR,
both in vivo (cardiac transplants to baboons [92]),
and in vitro (protection of hDAF-expressing porcine
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endothelial cells against the combined action of
human xenoreactive antibodies and complement
[90,91]).
To modify the glycosylation of the donor tissue, a
simple approach would be to treat the tissue with a
glycosidase, such as K-galactosidase. In case of a
vascularized organ one could thus remove most of
the GalK1,3Gal from the endothelium prior to trans-
plantation. The disadvantage, however, is that most
likely the K-gal glycotopes will rapidly re-appear as a
result of de novo synthesis, and transport to the cell
surface. It is conceivable that expression of K-galac-
tosidase within the Golgi apparatus of a transgenic
animal would provide a more lasting e¡ect.
Alternatively, it has been considered to modify
glycosyltransferase expression via gene inactivation
in transgenic animals, or by altering the expression
of the relevant gene by modi¢cation of the promoter.
Here, a major target would be the K3GalT gene.
Suppression of its expression would result in a global
modi¢cation of the cell surface, and induce an K-gal3
phenotype. Indeed, an analysis of transgenic mice
that were homozygous null-mutants for K3GalT
showed the absence of the K-gal glycotope in all tis-
sues examined [56,57]. It is anticipated that, simi-
larly, in pig null mutants all K1,3-galactosylation
will be abolished. However, it may be preferable to
limit K3GalT suppression to certain tissues only.
Cell-type speci¢c gene ablation could be accom-
plished using Cre-recombinase, or by speci¢c muta-
tions in the K3GalT promoter. It has been reported
recently that K3GalT gene expression in porcine en-
dothelial cells is regulated in a cell-type speci¢c way
[93]. Activation of endothelial cells resulted in a tran-
sient decrease in gene transcription, and correlated
with decreased K3GalT protein stability.
Another possibility to suppress the K-gal glycotope
would be the production of transgenic pigs that ex-
press a glycosyltransferase competing with the action
of K3GalT, or masking the K-gal glycotope. It is
known that terminal GalL1,4GlcNAc sequences
serve as an acceptor for multiple glycosyltransferases
including K3GalT. Certain glycosyltransferases di-
rectly compete with K3GalT for available acceptor
sites (i.e. an alternative sugar takes the place of the
K1,3-linked galactose residue). For example, if K2,3-
sialyltransferase is expressed in an early Golgi com-
partment, it will attach sialic acid residues to the 3-
position of terminal galactose residues on complex-
type N-glycans, thus blocking K1,3-galactosylation.
Indeed, overexpression of K2,3-sialyltransferase in
transfected porcine endothelial cells in tissue culture
reduced both their binding of GSI-B4 lectin and the
sensitivity to lysis mediated by complement and hu-
man serum [94]. These observations di¡er from pre-
liminary data reported earlier by Sharma et al. [95],
but as experimental details are not available it is not
clear if these studies can be compared.
Indirect competition is often the result of the strin-
gent acceptor substrate speci¢city of the glycosyl-
transferases. Substitution of the K3GalT acceptor
(GalL1,4GlcNAc-R) with another sugar residue
may hinder the action of K3GalT; examples are the
competition of K3GalT with K2,6-sialyltransferase,
with K1,2-fucosyltransferase H, or with an K1,3-
fucosyltransferase. Competition between K3GalT
and the H transferase in transfected CHO cells
led to an increased formation of the H antigen,
at the expense of the K-gal glycotope. Similarly,
the expression of the human H fucosyltransferase
in transgenic mice and pigs resulted in a high ex-
pression of the H antigen, together with a strong
reduction in the expression of the GalK1,3Gal struc-
ture [95]. This resulted in a decreased binding of
xenoreactive antibodies to endothelial cells of
the transgenic animals, and in a protection from
complement-mediated lysis. Similar observations
had earlier been made on xenogeneic cells in tissue
culture that expressed human K1,2-fucosyltransferase
[96].
7. Protective roles of the natural anti-GalK1,3Gal
antibody
The anti-GalK1,3Gal antibody is of clinical rele-
vance, as it is the major antibody directly responsible
for HAR, and is also involved in antibody-dependent
cellular rejection. A lasting depletion of this antibody
from the human circulation therefore seemed to be a
promising strategy to prevent HAR and thus to fa-
cilitate xenograft transplantation. Unfortunately, it is
likely that the anti-GalK1,3Gal antibody has a role in
providing protection against various pathogens that
carry GalK1,3Gal structures on their surface. These
pathogens may include parasites, such as Trypano-
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somes and Leishmania, bacteria, and various envel-
oped viruses.
In Leishmania and Trypanosomes, indirect evi-
dence suggests that GalK1,3Gal structures may be
present both on glycolipids and glycoproteins
[97,98]. Also, in Leishmania, lipophosphoglycans
may contain internal K1,3-linked Gal in the glycan
core which is linked to a phosphatidyl-inositol an-
chor [99]. These structures are a potential target for
the natural anti-K-gal antibody.
Retroviruses produced in non-primate species fre-
quently carry glycoproteins on their envelope with
carbohydrate moieties that re£ect the biosynthetic
capacities of the host organism. For example, retro-
viral glycoproteins produced in mouse and porcine
cells are likely to be K1,3-galactosylated. Indeed, the
anti-K-gal antibody was shown to be responsible for
complement activation and virolysis of murine de-
rived retroviruses in primate sera [64]. Similarly, vi-
rus particles produced in cells transfected with
K3GalT will carry K-gal glycotopes on their surface,
and as a result become sensitive to complement-
mediated lysis in contact with human serum [100].
Once introduced into the human blood stream, these
virus particles will be opsonized by the anti-GalK1,3-
Gal antibody, and be inactivated. A similar mecha-
nism would protect humans against pig endogenous
retroviruses that can be mobilized from the pig ge-
nome, and be secreted from a transplanted pig organ
into the recipient. However, the protection thus af-
forded against the pathogen may fail if anti-K-gal
antibody is permanently removed from the blood
stream. In particular, the elimination of human B
cell clones producing the anti-GalK1,3Gal antibody
may constitute a serious risk, by leaving the recipient
unprotected.
Another risk is the production of virus particles
that lack GalK1,3Gal structures. It has been shown
that a subset of human cell lines in tissue culture
(thus, in the absence of the anti-GalK1,3Gal anti-
body) can be infected by pig endogenous retroviruses
[63]. Moreover, co-cultivation of human cells with
porcine endothelial cells resulted in a broader subset
of tissue culture cell lines that could be infected.
Following passage through human cells, the pig ret-
roviruses could rescue a Moloney retroviral vector,
and acquired resistance to lysis by human comple-
ment. So, if pathogens are produced from the tissues
of an animal which does not express GalK1,3Gal
glycotopes, they may go unnoticed by the immune
system. Thus, suppression of K1,3-galactosylation in
porcine organs may increase the possibility of inter-
species viral transmission. In this way, complement-
mediated inactivation of retroviruses in human se-
rum triggered by anti-GalK1,3Gal, a unique type of
natural immunity, would be rendered non-functional
[64,101]. This factor will need to be taken into ac-
count by the time the technology becomes available
to produce transgenic pigs lacking K3GalT through
recombination in embryonic stem cells, or by nuclear
transfer methodology. The transgenic mice in which
K3GalT has been inactivated, and which as a result
develop a natural anti-K-gal antibody, will be an im-
portant model system to assess the importance of
anti-K-gal in immunity against retroviruses [56].
8. Future directions
The identi¢cation of the major carbohydrate anti-
gen mediating HAR in pig-to-human rejection, to-
gether with the cloning and the characterization of
the K1,3-galactosyltransferase responsible for its pro-
duction, has opened new avenues for the prevention
of HAR. The production of recombinant K3GalT
allows the synthesis of ligands for immunoadsorp-
tion, and for speci¢c intravenous carbohydrate ther-
apy. An analysis of K3GalT gene expression patterns
has helped to explain the distribution of the anti-
GalK1,3Gal antibody, and to understand the natural,
complement-mediated immunity against interspecies
retroviral transmission. The cloning of K3GalT ge-
nomic sequences has already allowed to generate an-
imals devoid of enzyme expression by homologous
recombination.
Although carbohydrate epitopes other than
GalK1,3Gal might play a role in rejection, with the
availability of carbohydrate-directed therapy it is
likely that the HAR will soon be overcome. It re-
mains a matter of debate, though, which approach
is most suitable here. Both a lasting suppression of
the production of anti-GalK1,3Gal antibodies in hu-
man recipients and the long-term e¡ects of pharma-
cologic immunosuppression are undesirable. We be-
lieve that, preferentially, e¡orts should be directed
both at the donor and the recipient. Most promising
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seems a combination of strategies such as the expres-
sion of human complement inhibitors, together with
a local modi¢cation of the glycosylation of the donor
tissue, and a temporary removal or blocking of the
anti-GalK1,3Gal antibody. Once delayed and chronic
e¡ects, which most likely involve interactions di¡er-
ent from anti-K-gal binding, are under control, one
could hope to reach the stage of accommodation
which might guarantee a long-term survival of the
transplanted organ. The former processes will be
the next problems to be tackled in the ¢eld of pig-
to-human xenotransplantation.
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